U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Waldenstrom macroglobulinemia

MedGen UID:
6174
•Concept ID:
C0024419
•
Neoplastic Process
Synonym: Waldenström macroglobulinemia
SNOMED CT: Waldenström macroglobulinemia (190818004); Waldenstrom macroglobulinemia (35562000); Macroglobulinemia (190817009); Waldenstrom's macroglobulinemia (190818004); Waldenstrom's macroglobulinemia (35562000); Primary macroglobulinemia (35562000)
Modes of inheritance:
Non-Mendelian inheritance
MedGen UID:
109109
•Concept ID:
C0600599
•
Genetic Function
Source: Orphanet
A mode of inheritance that depends on genetic determinants in more than one gene.
Non-Mendelian inheritance (Orphanet)
 
Related gene: MYD88
 
Monarch Initiative: MONDO:0100280
OMIM® Phenotypic series: PS153600
Orphanet: ORPHA33226

Definition

Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein. [from ORDO]

Professional guidelines

PubMed

Marginal zone lymphoma: 2023 update on diagnosis and management.
Cheah CY, Seymour JF
Am J Hematol 2023 Oct;98(10):1645-1657. Epub 2023 Aug 21 doi: 10.1002/ajh.27058. PMID: 37605344
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
IgM monoclonal gammopathies of clinical significance: diagnosis and management.
Khwaja J, D'Sa S, Minnema MC, Kersten MJ, Wechalekar A, Vos JM
Haematologica 2022 Sep 1;107(9):2037-2050. doi: 10.3324/haematol.2022.280953. PMID: 35770530Free PMC Article

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, 2023

Recent clinical studies

Etiology

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Managing Waldenström's macroglobulinemia with BTK inhibitors.
Buske C, Jurczak W, Salem JE, Dimopoulos MA
Leukemia 2023 Jan;37(1):35-46. Epub 2022 Nov 19 doi: 10.1038/s41375-022-01732-9. PMID: 36402930Free PMC Article
Monoclonal Gammopathy of Undetermined Significance.
Gonsalves WI, Rajkumar SV
Ann Intern Med 2022 Dec;175(12):ITC177-ITC192. Epub 2022 Dec 13 doi: 10.7326/AITC202212200. PMID: 36508741
Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual.
Gertz MA
J Clin Oncol 2022 Aug 10;40(23):2600-2608. Epub 2022 Jun 14 doi: 10.1200/JCO.22.00495. PMID: 35700418Free PMC Article
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, Tsakmaklis N, Chen JG, Kofides A, Sklavenitis-Pistofidis R, Bustoros M, Keezer A, Meid K, Patterson CJ, Sacco A, Roccaro A, Branagan AR, Yang G, Ghobrial IM, Castillo JJ
J Clin Oncol 2020 Apr 10;38(11):1198-1208. Epub 2020 Feb 21 doi: 10.1200/JCO.19.02314. PMID: 32083995Free PMC Article

Diagnosis

How to manage waldenström's macroglobulinemia in 2024.
Grunenberg A, Buske C
Cancer Treat Rev 2024 Apr;125:102715. Epub 2024 Mar 5 doi: 10.1016/j.ctrv.2024.102715. PMID: 38471356
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. PMID: 33368476
How I treat Waldenström macroglobulinemia.
Dimopoulos MA, Kastritis E
Blood 2019 Dec 5;134(23):2022-2035. doi: 10.1182/blood.2019000725. PMID: 31527073
Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.
Juárez-Salcedo LM, Castillo JJ
Hematol Oncol Clin North Am 2019 Aug;33(4):639-656. Epub 2019 Apr 30 doi: 10.1016/j.hoc.2019.03.004. PMID: 31229160

Therapy

Current approach to Waldenström macroglobulinemia.
Kapoor P, Rajkumar SV
Blood Rev 2023 Nov;62:101129. Epub 2023 Aug 26 doi: 10.1016/j.blre.2023.101129. PMID: 37659912Free PMC Article
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Current approach to Waldenström Macroglobulinemia.
Ravi G, Kapoor P
Cancer Treat Res Commun 2022;31:100527. Epub 2022 Feb 2 doi: 10.1016/j.ctarc.2022.100527. PMID: 35149375
How I treat Waldenström macroglobulinemia.
Dimopoulos MA, Kastritis E
Blood 2019 Dec 5;134(23):2022-2035. doi: 10.1182/blood.2019000725. PMID: 31527073
Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.
Juárez-Salcedo LM, Castillo JJ
Hematol Oncol Clin North Am 2019 Aug;33(4):639-656. Epub 2019 Apr 30 doi: 10.1016/j.hoc.2019.03.004. PMID: 31229160

Prognosis

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Current approach to Waldenström Macroglobulinemia.
Ravi G, Kapoor P
Cancer Treat Res Commun 2022;31:100527. Epub 2022 Feb 2 doi: 10.1016/j.ctarc.2022.100527. PMID: 35149375
Waldenström macroglobulinemia.
Baďurová K, Gregorová J, Vlachová M, Krejčí M, Ševčíková S
Klin Onkol 2021 Fall;34(6):428-433. doi: 10.48095/ccko2021428. PMID: 34911327
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M
Blood 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. PMID: 32731259Free PMC Article
Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.
Juárez-Salcedo LM, Castillo JJ
Hematol Oncol Clin North Am 2019 Aug;33(4):639-656. Epub 2019 Apr 30 doi: 10.1016/j.hoc.2019.03.004. PMID: 31229160

Clinical prediction guides

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. PMID: 33368476
Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.
Juárez-Salcedo LM, Castillo JJ
Hematol Oncol Clin North Am 2019 Aug;33(4):639-656. Epub 2019 Apr 30 doi: 10.1016/j.hoc.2019.03.004. PMID: 31229160
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR
N Engl J Med 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710. PMID: 22931316
Waldenström macroglobulinemia.
Vijay A, Gertz MA
Blood 2007 Jun 15;109(12):5096-103. Epub 2007 Feb 15 doi: 10.1182/blood-2006-11-055012. PMID: 17303694

Recent systematic reviews

Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis.
Chan WL, Chong VCL, Wee IJY, Poon LM, Chan EHL, Lee J, Chee YL, Jeyasekharan AD, Chng WJ, Samuel M, de Mel S
Blood Cancer J 2023 Sep 7;13(1):140. doi: 10.1038/s41408-023-00916-5. PMID: 37679351Free PMC Article
Priapism in Lymphoproliferative Disorders: A Systematic Review.
Ali EA, Sardar S, Yassin MA
Hematol Oncol Stem Cell Ther 2022 Dec 23;15(4):176-182. doi: 10.1016/j.hemonc.2021.05.003. PMID: 34157311
Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
Parrondo RD, Reljic T, Iqbal M, Ayala E, Tun HW, Kharfan-Dabaja MA, Kumar A, Murthy HS
Clin Lymphoma Myeloma Leuk 2020 Oct;20(10):e694-e711. Epub 2020 Jun 2 doi: 10.1016/j.clml.2020.05.021. PMID: 32616401
CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP
Expert Rev Hematol 2019 Oct;12(10):873-881. Epub 2019 Jul 30 doi: 10.1080/17474086.2019.1649132. PMID: 31343930
Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies.
Lepretre S, Dartigeas C, Feugier P, Marty M, Salles G
Leuk Lymphoma 2016;57(4):852-65. Epub 2015 Oct 8 doi: 10.3109/10428194.2015.1085528. PMID: 26308278

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2023
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, 2023

    Reviews

    Related information

    • MeSH
      Related Medical Subject Headings
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...